SKSabine Klein

Sabine Klein

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sabine Klein has a total of 203 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Single-cell profiling reveals monocyte mitochondrial dysfunction in patients with cirrhosis progressing to acute-on-chronic liver failure

    by Theresa Hildegard Wirtz, Sara Palomino-Echeverria, Maike Rebecca Pollmanns, Estefanía Huergo, Felix Schreibing, Johanna Reißing, Cristina Sánchez-Garrido, Cristina López-Vicario, Ana Maria Aransay, Maurizio Baldassarre, et al.

  • Open Access

    Postmenopausal estradiol levels and female sex modulate haemodynamic responsiveness in experimental portal hypertension

    by Fabian Schachteli, Sabine Klein, Robert Schierwagen, Julia Fischer, Kai-Henrik Peiffer, Manfred Fobker, Elena Vorona, Sania Arif, Sara Zarei, Maximilian Joseph Brol, et al.

  • Open Access

    Posttranscriptional reprogramming controls MASLD progression through chronic ER stress adaptation

    by Eulalia Belloc, Vittorio Calderone, Salvador Naranjo-Suarez, Lidia Mateo, Judit Martin, Florencia Malizia, Annarita Sibilio, Veronica Chanes, Marta Ramirez-Pedraza, M. Eugenia Delgado, et al.

    Metabolic dysfunction-associated steatohepatitis (MASH) and its progression to hepatocellular carcinoma remain major clinical challenges. Chronic endoplasmic reticulum (ER) stress, induced by sustained high-fat diet (HFD) intake, promotes hepatic inflammation, lipid accumulation, and hepatocellular dysfunction during MASH pathogenesis. While transcriptional responses are well characterized, the posttranscriptional mechanisms underlying hepatocyte adaptation to chronic ER stress remain poorly understood. Using an integrative approach combining transcriptomics, ribosome profiling, cytoplasmic polyadenylation analysis, and cis-regulatory mapping, we define the posttranscriptional landscape induced by chronic HFD exposure. To delineate the specific role of chronic ER stress, we use a hepatocyte-specific knockout of a key regulator of translational control under prolonged ER stress. We show that ~70% of HFD-induced gene expression changes are modulated at the translational level. A distinct subset of mRNAs, enriched in suboptimal codons and bearing short poly(A) tails under normal diet, becomes selectively activated upon HFD-induced poly(A) tail elongation. These transcripts, associated with cell cycle, immune response, fibrosis, and tissue remodeling, correlate with MASH severity in both murine models and human samples. Their regulation is mediated by cis-elements in the 3′ UTR that coordinate polyadenylation and deadenylation. Loss of this adaptive response exacerbates liver damage and tumor burden in HFD-fed mice.


  • Open Access

    Higher prevalence of cytomegalovirus and Epstein–Barr virus in acute-on-chronic liver failure

    by Keerthihan Thiyagarajah, Jannik Sonnenberg, Esra Görgülü, Pia Lembeck, Nico Kraus, Mirco Glitscher, Frank Erhard Uschner, Maximilian Joseph Brol, Wenyi Gu, Robert Schierwagen, et al.


  • Open Access

    Decompensated MASH-Cirrhosis Model by Acute and Toxic Effects of Phenobarbital

    by Nico Kraus, Frank Erhard Uschner, Magnus Moeslein, Robert Schierwagen, Wenyi Gu, Maximilian Joseph Brol, Eike Fürst, Inga Grünewald, Sophie Lotersztajn, Pierre-Emmanuel Rautou, et al.

    Metabolic dysfunction-associated Steatohepatitis (MASH), is a prominent cause for liver cirrhosis. MASH-cirrhosis is responsible for liver complications and there is no specific treatment. To develop new therapeutic approaches, animal models are needed. The aim of this study was to develop a fast animal model of MASH-cirrhosis in rats reflecting the human disease. Carbon tetrachloride (CCl4) injections in combination with a high-fat Western diet (WD) were used to induce MASH-cirrhosis. To accelerate liver injury, animals received phenobarbital (PB) in their drinking water using two different regimens. Rats developed advanced MASH-cirrhosis characterized by portal hypertension, blood biochemistry, hepatic ballooning, steatosis, inflammation and fibrosis. Importantly, rats receiving low-dose PB for the long term (LT) showed ascites after 6 weeks, whereas rats with high-dose short-term (ST) PB developed ascites after 8 weeks. ST- and LT-treated rats showed increased portal pressure (PP) and decreased mean arterial pressure (MAP). Of note, hepatocyte ballooning was only observed in the LT group. The LT administration of low-dose PB with CCl4 intoxication and WD represents a fast and reproducible rat model mimicking decompensated MASH-cirrhosis in humans. Thus, CCl4 + WD with LT low-dose phenobarbital treatment might be the preferred rat animal model for drug development in MASH-cirrhosis.


  • Open Access

    Stage of fibrosis is not a predictive determinant of weight loss in patients undergoing bariatric surgery

    by Maximilian Joseph Brol, Uta Drebber, Xiaojie Yu, Robert Schierwagen, Wenyi Gu, Andreas Plamper, Sabine Klein, Margarete Odenthal, Frank Erhard Uschner, Michael Praktiknjo, et al.


  • Open Access

    The Role of Hypoxia-Inducible Factor 1 Alpha in Acute-on-Chronic Liver Failure

    by Marcus M. Mücke, Nihad El Bali, Katharina M. Schwarzkopf, Frank Erhard Uschner, Nico Kraus, Larissa Eberle, Victoria Therese Mücke, Julia Bein, Sandra Beyer, Peter J. Wild, et al.

    Acute-on-chronic liver failure (ACLF) is associated with increased mortality. Specific therapy options are limited. Hypoxia-inducible factor 1 alpha (HIF-1α) has been linked to the pathogenesis of chronic liver disease (CLD), but the role of HIF-1α in ACLF is poorly understood. In the current study, different etiologies of CLD and precipitating events triggering ACLF were used in four rodent models. HIF-1α expression and the intracellular pathway of HIF-1α induction were investigated using real-time quantitative PCR. The results were verified by Western blotting and immunohistochemistry for extrahepatic HIF-1α expression using transcriptome analysis. Exploratory immunohistochemical staining was performed to assess HIF-1α in human liver tissue. Intrahepatic HIF-1α expression was significantly increased in all animals with ACLF, regardless of the underlying etiology of CLD or the precipitating event. The induction of HIF-1α was accompanied by the increased mRNA expression of NFkB1 and STAT3 and resulted in a marked elevation of mRNA levels of its downstream genes. Extrahepatic HIF-1α expression was not elevated. In human liver tissue samples, HIF-1α expression was elevated in CLD and ACLF. Increased intrahepatic HIF-1α expression seems to play an important role in the pathogenesis of ACLF, and future studies are pending to investigate the role of therapeutic HIF inhibitors in ACLF.

  • Open Access

    Differential Lipidomics, Metabolomics and Immunological Analysis of Alcoholic and Non-Alcoholic Steatohepatitis in Mice

    by Erika Dorochow, Nico Kraus, Nicolas Chenaux-Repond, Sandra Pierre, Anja Kolbinger, Gerd Geisslinger, Cristina Ortiz, Christoph Welsch, Jonel Trebicka, Robert Gurke, et al.

    Non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis (ASH) are the leading causes of liver disease worldwide. To identify disease-specific pathomechanisms, we analyzed the lipidome, metabolome and immune cell recruitment in livers in both diseases. Mice harboring ASH or NASH had comparable disease severities regarding mortality rate, neurological behavior, expression of fibrosis marker and albumin levels. Lipid droplet size was higher in NASH than ASH and qualitative differences in the lipidome were mainly based on incorporation of diet-specific fatty acids into triglycerides, phosphatidylcholines and lysophosphatidylcholines. Metabolomic analysis showed downregulated nucleoside levels in both models. Here, the corresponding uremic metabolites were only upregulated in NASH suggesting stronger cellular senescence, which was supported by lower antioxidant levels in NASH as compared to ASH. While altered urea cycle metabolites suggest increased nitric oxide synthesis in both models, in ASH, this depended on increased L-homoarginine levels indicating a cardiovascular response mechanism. Interestingly, only in NASH were the levels of tryptophan and its anti-inflammatory metabolite kynurenine upregulated. Fittingly, high-content immunohistochemistry showed a decreased macrophage recruitment and an increased polarization towards M2-like macrophages in NASH. In conclusion, with comparable disease severity in both models, higher lipid storage, oxidative stress and tryptophan/kynurenine levels were seen in NASH, leading to distinct immune responses.


  • Regulation of Uridine Diphosphate-Glucuronosyltransferase 1A Expression by miRNA-214-5p and miRNA-486-3p

    by Stefan Paulusch, Sandra Kalthoff, Steffen Landerer, Christian Jansen, Robert Schierwagen, Sabine Klein, Jonel Trebicka, Christian P Strassburg

    Aim: This study aimed to identify novel miRNAs (miRs) as regulators of UGT1A gene expression and to evaluate them as potential risk factors for the development of liver fibrosis/cirrhosis. Material...


  • Contents

    by Joan Cordona, Rafael Esteban, Stefan Zeuzem, Ralph DeMasi, Alessandra Baldini, Bruce Coate, Dayong Luo, Joseph Mrus, James Witek, Hamish Innes, et al.